SkylineDx at the forefront of a genomic revolution
SkylineDx is dedicated to optimize therapeutic decision making through the development of molecular diagnostic tests for blood cancers and thereby improving the quality of life of blood cancer patients.Discover more
Learn more about MMprofiler™, the lead product of SkylineDx. It is a prognostic test to determine the level of risk of a multiple myeloma patient by classifying such patient into a “high” or “standard” risk group with the use of the novel SKY92 gene signature.Learn more
01 Dec 2015
SkylineDx to Present New Data Demonstrating Prognostic Value of MMprofiler™ in Multiple Myeloma at American Society of Hematology Annual Meeting
Studies Support Use of MMprofiler™ for Stratifying High and Low-Risk in Newly Diagnosed Elderly and Relapsed Patients MassGen Poster Highlights Use of MMprofiler™ in Phase II Modified RVD (Revlimid/Velcade/Dexamethasone) Trial ...
30 Mar 2016 - 01 Apr 2016, Radboud UMC, Nijmegen
4th Int'l Workshop Cancer Genetic & Cytogenetic Diagnostics
03 Jun 2016 - 07 Jun 2016, McCormick Place, Chicago, Illinois
American Society Of Clinical Oncology (ASCO) - Annual Meeting
06 Jun 2016 - 09 Jun 2016, San Francisco
BIO International Convention
A short video introducing SkylineDx’s new molecular prognostic test for multiple myeloma (MM): the MMprofiler.
SkylineDx is a pioneer in the field of molecular diagnostics through developing and commercializing innovative, signature-based diagnostics with a high clinical value that help to provide physicians and patients with the best individual care possible.